Summary
Ninety-eight female patients (mean age 54 years) who underwent doxorubicin therapy because of metastatic breast cancer were submitted to radionuclide angiography at rest. Left ventricular ejection fractions (LVEFs) were found to decrease significantly with the increasing cumulative doxorubicin dosage. Patients with prior local radiotherapy showed lower LVEFs at the same dosage level than nonirradiated patients, but the difference was not statistically significant. In a further study, 52 patients (mean age 56 years) were followed up regularly for their history and systolic time intervals prior to each doxorubicin treatment course. Before starting treatment, LVEF values were normal in all cases. Fifteen of these patients complained of dyspnea at some time during the treatment period before the critical cumulative dosage level of 550 mg/m2 was reached. Nine of these 15 patients showed an increase of the PEPI:LVETI ratio (≧0.40) and 12 patients a decrease of the LVEF values at rest at the same time. The rest of the patients did not complain of cardiac symptoms and did not show any significant alterations in systolic-time-interval measurements until the borderline dosage level (550 mg/m2) was attained. To evaluate myocardial function with greater accuracy, these 15 patients were submitted to right-heart catheterization and radionuclide angiography at rest and during exercise. As a result, doxorubiciri treatment had to be discontinued in three of these patients because of heart failure of stage III or IV and treatment with methyl digoxin and nifedipine was started. In these three patients cardiotonic medication could produce more or less complete cardiac recompensation.
We conclude from our findings that signs of stage-III heart failure in radionuclide angiography performed while the patient is at rest and exercising should be regarded as the upper limit of the therapeutic risk, where further doxorubicin treatment is contraindicated. Cardiotonic medication during cytostatic courses should be avoided, however, because the true functional condition of the myocardium could be masked during a potentially cardiotoxic therapy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Ashburn WL, Schelbert HR, Verba JW (1978) Left ventricular ejection fraction—a review of several radionuclide angiographic approaches using the scintillation camera. Prog Cardiovasc Dis 20:267–284
Bianco AJ, Schafer RB (1979) Radionuclide methods in the assessment of left ventricular function. Am J Med Sci 277:244–254
Blum RH, Carter SK (1974) Adriamycin: A new anticancer drug with significant clinical activity. Ann Intern Med 80:249–259
Blum RH, Corson JM, Wilson RE, Greenberger JS, Canellos GP, Frei E (1980) Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD) Cancer 46:1722–1726
Borer JS, Kent KM, Bacharach SL, Green MV, Rosing DR, Seides SF, Epstein SE, Johnston GS (1979) Sensitivity specificity and predictive accuracy of radionuclide cineangiography during exercise in patients with coronary artery disease. Comparison with exercise electrocardiography. Circulation 60:572–580
Brady TJ, Thrall JH, Clare JM, Rogers WL, Lo K, PittB (1979) Exercise radionuclide ventriculography: practical considerations and sensitivity in coronary artery disease detection Radiology 132:697–702
Bristow MR, Mason JW, Billingham ME, Daniels JR (1978) Doxorubucin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 88:168–175
Bristow MR, Mason JW, Billingham ME, Daniels JR (1981) Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 102:709–718
Bühlmann A (1965) Klinische Funktionsprüfung des Herzens. Schweiz Med Wochenschr 95:1327–1332
Bühner R, Bidert S, Miura D (1980) Erhöhung des frei-ionisierten zytoplasmatischen Calciums als Ursache der Adriamycin-Kardiomyopathie. Klin Wochenschr 58:747–748
Cortes EP, Gupta M, Chou C, Amin VC, Folkers K (1978) Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat Rep 62:887–891
Goornaghtigh E, Chatelain P, Caspers J, Ruysschaert JM (1980) Evidence of a specific complex between adriamycin and negatively-charged phospholipids. Biochim Biophys Acta 597:1–14
Gupta M, Cortes EP, Mundia A (1976) Systolic time interval (STI) in adriamycin (ADM) treated patients on digoxin or prednisone cardioprophylaxis. Proc Am Assoc Cancer Res ASCO 17:269–272
Lefrak EA, Pitha J, Rosenheim S, Gottlieb J (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32:302–314
Lenzhofer R, Dudczak R, Dittrich C, Gumhold G, Moser K, Spitzy KH (1983a) Systolische Zeitintervallmessung zur Überwachung der Herzfunktion unter Adriamycintherapie bei Patientinnen mit metastasierten Mammakarzinomen. Dtsch Med Wochenschr 20:771–775
Lenzhofer R, Magometschnigg D, Dudczak R, Bolebruch C, Moser K (1983b) Indication of reduced doxorubicin-induced cardiac toxicity by additional treatment with antioxidative substances. Experientia 39:62–64
Livingston RB, Moore TN, Heilbrunn L, Bottomley R, Lehane D, Rivkin SE, Thigpen T (1978) Small-cell carcinoma of the lung: combined chemotherapy and radiation: a Southwest Oncology Group study. Ann Intern Med 88:194–199
Minow RA, Benjamin RS, Gottlieb JA (1975) Adriamycin (NSC-123127) cardiomyopathy: An overview with determination of risk factors. Cancer Chemother Rep 6:195–201
Morgan GW, McIlveen BM, Freedman A, Murray IPC (1981) Radionuclide ejection fraction in doxorubicin cardiotoxicity. Cancer Treat Rep 65:629–638
O'Bryan RM, Baker LH, Gottlieb JA, Rivkin SE, Balcerzak SP, Grumet GN, Salmon SE, Moon TE, Hoogstraaten B (1977) Dose response evaluation of adriamycin in human neoplasia. Cancer 39:1940–1948
Reindell H, Roskamm H (1977) Herzkrankheiten-Pathophysiologie, Diagnostik, Therapie. Springer, Berlin Heidelberg New York
Sachs L (1972) Statistische Auswertungsmethoden, 3. Auflage. Springer, Berlin Heidelberg New York
Salmon SE, Jones SE (1979) Studies of the combination of adriamycin and cyclophosphamide (alone or with other agents) for the treatment of breast cancer. Oncology 36:40–47
Samek L, Roskamm H (1980) Das Belastungs-EKG. In: Csapo G (ed) Konventionelle und intracardiale Elektrokardiographie. Documenta Geigy
Shuman RD, Ettinger DS, Abeloff MD, Livengood SV, Fortuin NJ (1981) Comparative analysis of noninvasive cardiac parameters in the detection and evaluation of adriamycin cardiotoxicity. Johns Hopkins Med J 149:57–63
Stafford RW, Harris WS, Weissler AM (1970) Left ventricular systolic time intervals as indices of postural circulatory stress in man. Circulation 41:485–492
Weissler AM, Harris WS, Schoenfeld CD (1969) Bedside technics for the evaluation of ventricular function in man. Am J Cardiol 23:577–583
Williams CJ (1978) Doxorubicin cardiotoxicity: role of digoxin in prevention. Br Med J 1:176
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lenzhofer, R., Dudczak, R., Gumhold, G. et al. Noninvasive methods for the early detection of doxorubicin-induced cardiomyopathy. J Cancer Res Clin Oncol 106, 136–142 (1983). https://doi.org/10.1007/BF00395392
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00395392